Follow The Filings

TVRD Tvardi Therapeutics Inc.

Health Care, filed as TVARDI THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 exit

In 2026 Q2 Farallon Capital Management sold out of Tvardi Therapeutics.

Who owns TVRD

Sorted by value, long equity only, as of 2026 Q2.

History
Farallon Capital Management exited 2026 Q2 Last 2026 Q1 <0.01% Exit 0.00% 21,438 $68K History

0 current, 1 exited last period, options excluded

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 7.01,9.01 Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
424B3 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 8.01 Filing Doc
424B3 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 5.02 Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
424B3 Filing Doc
S-1/A Filing Doc

Insider forms

Forms 3, 4 and 5 from EDGAR, 3 rows shown

Filed Form Detail Links
4 Period Jun 9, 2026 (5 forms) Filing Doc
4 Period Jan 29, 2026 (4 forms) Filing Doc
4 Period Dec 16, 2025 (4 forms) Filing Doc

Source: SEC EDGAR submissions, updated 13 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $20.97M $7.14M —
Net income -$118.51M -$70.87M -$18.21M
Net margin * -565.2% -993.0% —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $116.16M $43.83M $31.54M
Total non-current assets * $9.69M $0M $0.535M
Total assets $125.84M $43.83M $32.07M
Total current liabilities $25.59M $3.97M $11.04M
Total non-current liabilities * $43.17M $44.45M $0.085M
Total equity $57.08M -$4.59M $20.95M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$92.08M -$60.92M -$23.5M
Cash from investing $43.46M $48.74M -$10.08M
Cash from financing $38.15M -$3.6M $22.7M
Net change in cash * -$10.47M -$15.78M -$10.88M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.